Results 211 to 220 of about 6,944 (246)

Adverse Liver and Renal Outcomes After Initiating SGLT-2i and GLP-1RA Therapy Among Patients With Diabetes and MASLD. [PDF]

J Diabetes
Krishnan A, Schneider CV, Mukherjee D, Woreta TA, Alqahtani SA.   +4 more
europepmc   +1 more source

GIP/GLP-1RA as adjunctive to automated insulin delivery in adults with Type 1 diabetes (the AID-JUNCT trial): Study protocol for a prospective, randomized, clinical trial. [PDF]

PLoS One
Fragozo-Ramos MC, Schenker G, Hepprich M, Gallo-Villegas J, Züger T, Garcia-Tirado J.   +5 more
europepmc   +1 more source

An overview of randomized clinical trials of fixed-ratio combinations of basal insulin plus GLP-1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes. [PDF]

Diabetes Obes Metab
Bolli GB, Porcellati F, Lucidi P, Fanelli CG, Perseghin G, Horowitz M, Owens DR.   +6 more
europepmc   +1 more source

The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required. [PDF]

Metabolites
Sinclair AJ, Abdelhafiz AH.
europepmc   +1 more source

Can the incidence of voluntarily reported side effects support the argument for a clinically relevant GLP-1RA tachyphylaxis? Comment on Br J Anaesth 2025; 134:1486-1496. [PDF]

Br J Anaesth
Hobai IA.
europepmc   +1 more source

Enhancing Patient Outcomes: Prioritizing SGLT2is and GLP-1RAs in Diabetes with CVD

Diabetes & Metabolism Journal
openaire   +3 more sources

Comment on: GLP-1RA and SGLT2i utilization in people with type 2 diabetes with atherosclerotic cardiovascular disease (ASCVD) or at high risk of ASCVD in the Gulf Region. [PDF]

Saudi Med J
europepmc   +1 more source

Letter: Methodological Concerns Regarding GLP-1RA Effects on MASLD Outcomes

Clinical and Molecular Hepatology
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients

Current Hypertension Reviews, 2021
Background:Diabetes is a chronic disease with high complexity that demands strategic medical care with a multifactorial risk-reduction approach. Over the past decade, the treatment of type 2 diabetes mellitus (T2DM) has entirely changed. One of the paradigm changes has been the arrival of new drugs that reduce cardiovascular risk beyond the reduction ...
Aschner Pablo, Blanc Evelyn, Folino Claudia, Morosán A. Yanina   +3 more
openaire   +2 more sources

The GLP-1RAs: From Evolution to Revolution

The Singapore Family Physician, 2022
Research on incretin hormones has advanced considerably over the past few decades. Although the initial molecule – glucose-dependent insulinotropic polypeptide – failed to stimulate insulin secretion in patients with type 2 diabetes, it led to the discovery of glucagon-like peptide 1 (GLP-1). As GLP-1 impacts on various tissues and cells throughout the
openaire   +1 more source